77 related articles for article (PubMed ID: 21485220)
1. [Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance].
Tang WM; Gou X; Liu QX
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jan; 27(1):97-8. PubMed ID: 21485220
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression.
Muramaki M; Miyake H; Yamada Y; Hara I
Oncol Rep; 2006 Jan; 15(1):253-7. PubMed ID: 16328065
[TBL] [Abstract][Full Text] [Related]
4. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
Meyer-Siegler KL; Iczkowski KA; Vera PL
BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
[TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor in cancer.
Yasasever V; Camlica H; Duranyildiz D; Oguz H; Tas F; Dalay N
Cancer Invest; 2007 Dec; 25(8):715-9. PubMed ID: 18058468
[TBL] [Abstract][Full Text] [Related]
6. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
Stephan C; Xu C; Brown DA; Breit SN; Michael A; Nakamura T; Diamandis EP; Meyer H; Cammann H; Jung K
Prostate; 2006 May; 66(6):651-9. PubMed ID: 16388506
[TBL] [Abstract][Full Text] [Related]
7. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
8. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance.
Tomiyasu M; Yoshino I; Suemitsu R; Okamoto T; Sugimachi K
Clin Cancer Res; 2002 Dec; 8(12):3755-60. PubMed ID: 12473586
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor expression in ovarian cancer.
Agarwal R; Whang DH; Alvero AB; Visintin I; Lai Y; Segal EA; Schwartz P; Ward D; Rutherford T; Mor G
Am J Obstet Gynecol; 2007 Apr; 196(4):348.e1-5. PubMed ID: 17403417
[TBL] [Abstract][Full Text] [Related]
10. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer.
Xia HH; Yang Y; Chu KM; Gu Q; Zhang YY; He H; Wong WM; Leung SY; Yuen ST; Yuen MF; Chan AO; Wong BC
Cancer; 2009 Dec; 115(23):5441-9. PubMed ID: 19685530
[TBL] [Abstract][Full Text] [Related]
11. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas.
Lee H; Rhee H; Kang HJ; Kim HS; Min BS; Kim NK; Kim H
Am J Clin Pathol; 2008 May; 129(5):772-9. PubMed ID: 18426738
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
Khan N; Cromer CJ; Campa M; Patz EF
Cancer; 2004 Jul; 101(2):379-84. PubMed ID: 15241837
[TBL] [Abstract][Full Text] [Related]
13. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
14. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.
Kamimura A; Kamachi M; Nishihira J; Ogura S; Isobe H; Dosaka-Akita H; Ogata A; Shindoh M; Ohbuchi T; Kawakami Y
Cancer; 2000 Jul; 89(2):334-41. PubMed ID: 10918163
[TBL] [Abstract][Full Text] [Related]
15. Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris.
Namazi MR; Fallahzadeh MK; Shaghelani H; Kamali-Sarvestani E
Int J Dermatol; 2010 Feb; 49(2):146-8. PubMed ID: 19799642
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis.
Krockenberger M; Kranke P; Häusler S; Engel JB; Horn E; Nürnberger K; Wischhusen J; Dietl J; Hönig A
Anticancer Res; 2012 Dec; 32(12):5233-8. PubMed ID: 23225421
[TBL] [Abstract][Full Text] [Related]
17. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
18. Macrophage migration inhibitory factor plays a pivotal role in hepatocellular carcinoma and may be a noninvasive imaging target.
Han Y; Zhang C
Med Hypotheses; 2010 Dec; 75(6):530-2. PubMed ID: 20678866
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.
Xu X; Wang B; Ye C; Yao C; Lin Y; Huang X; Zhang Y; Wang S
Cancer Lett; 2008 Mar; 261(2):147-57. PubMed ID: 18171602
[TBL] [Abstract][Full Text] [Related]
20. [TPS in prostate cancer].
Rodríguez-Rubio FI; Monreal I; Robles JE; Martín-Marquina A; Abad JI; Rosell D; Zudaire JJ; Berián JM
Actas Urol Esp; 1995 Feb; 19(2):131-3. PubMed ID: 7539573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
